{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:11:17Z","timestamp":1792458677570,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1124\/pharmrev.120.000031","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T22:55:14Z","timestamp":1607554514000},"page":"152-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Cognitive Impairment in Older Adults and Therapeutic Strategies"],"prefix":"10.1016","volume":"73","author":[{"given":"Thomas J.","family":"Montine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000031_bib1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000031_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1523\/JNEUROSCI.17-02-00516.1997","article-title":"Plastic neuronal remodeling is impaired in patients with Alzheimer\u2019s disease carrying apolipoprotein epsilon 4 allele","volume":"17","author":"Arendt","year":"1997","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000031_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000031_bib4","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.3233\/JAD-179939","article-title":"Religious orders study and rush memory and aging project","volume":"64","author":"Bennett","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1124\/pharmrev.120.000031_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jamda.2019.03.001","article-title":"Sundown syndrome in older persons: a scoping review","volume":"20","author":"Boronat","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"10.1124\/pharmrev.120.000031_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ana.25380","article-title":"Attributable risk of Alzheimer\u2019s dementia attributed to age-related neuropathologies","volume":"85","author":"Boyle","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jalz.2010.11.007","article-title":"National estimates of the prevalence of Alzheimer\u2019s disease in the United States","volume":"7","author":"Brookmeyer","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature20412","article-title":"The road to restoring neural circuits for the treatment of Alzheimer\u2019s disease","volume":"539","author":"Canter","year":"2016","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000031_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajpath.2015.12.001","article-title":"Precision medicine: clarity for the complexity of dementia","volume":"186","author":"Cholerton","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1124\/pharmrev.120.000031_bib11","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1073\/pnas.1609896113","article-title":"Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes","volume":"113","author":"Chung","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000031_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.molmed.2011.06.004","article-title":"TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies","volume":"17","author":"Cohen","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1124\/pharmrev.120.000031_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/S0033291700049588","article-title":"The aftermath of boxing","volume":"3","author":"Corsellis","year":"1973","journal-title":"Psychol Med"},{"key":"10.1124\/pharmrev.120.000031_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.5858\/arpa.2016-0469-SA","article-title":"Hippocampal sclerosis in older patients: practical examples and guidance with a focus on cerebral age-related TDP-43 with sclerosis","volume":"141","author":"Cykowski","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1124\/pharmrev.120.000031_bib16","doi-asserted-by":"crossref","first-page":"eaay3069","DOI":"10.1126\/scitranslmed.aay3069","article-title":"APOE genotype regulates pathology and disease progression in synucleinopathy","volume":"12","author":"Davis","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000031_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF00293396","article-title":"Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans","volume":"88","author":"Dickson","year":"1994","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000031_bib18","series-title":"Dorland\u2019s Illustrated Medical Dictionary","author":"Dorland","year":"1981"},{"key":"10.1124\/pharmrev.120.000031_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0895-4356(90)90136-D","article-title":"Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study","volume":"43","author":"Farmer","year":"1990","journal-title":"J Clin Epidemiol"},{"key":"10.1124\/pharmrev.120.000031_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-981-32-9358-8_16","article-title":"Amyloid-\u03b2 and tau at the Crossroads of Alzheimer\u2019s disease","volume":"1184","author":"Gallardo","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/pharmrev.120.000031_bib21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet (2017) 389:e1]","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000031_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib23","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0b013e3182a351d4","article-title":"Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study","volume":"81","author":"Gelber","year":"2013","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000031_bib24","doi-asserted-by":"crossref","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"NEURODEGENERATION. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000031_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/febs.14004","article-title":"The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the \u201camyloid cascade hypothesis\u201d","volume":"284","author":"Hardy","year":"2017","journal-title":"FEBS J"},{"key":"10.1124\/pharmrev.120.000031_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases","volume":"72","author":"Huang","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000031_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","article-title":"ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion","volume":"168","author":"Huang","year":"2017","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000031_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib29","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.jacc.2019.04.034","article-title":"Vascular cognitive impairment and Dementia: JACC scientific expert panel","volume":"73","author":"Iadecola","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pharmrev.120.000031_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000031_bib32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.conb.2011.08.002","article-title":"Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer\u2019s disease","volume":"21","author":"Keene","year":"2011","journal-title":"Curr Opin Neurobiol"},{"key":"10.1124\/pharmrev.120.000031_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08037051.2018.1507621","article-title":"Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study","volume":"27","author":"Kjeldsen","year":"2018","journal-title":"Blood Press"},{"key":"10.1124\/pharmrev.120.000031_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1515\/revneuro-2017-0006","article-title":"Alzheimer\u2019s disease: as it was in the beginning","volume":"28","author":"Kozlov","year":"2017","journal-title":"Rev Neurosci"},{"key":"10.1124\/pharmrev.120.000031_bib35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing [published correction appears in Nat Genet (2019) 51:1423\u20131424]","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000031_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jnen\/nlx030","article-title":"Resistance to Alzheimer disease neuropathologic changes and apparent cognitive resilience in the nun and Honolulu-Asia aging studies","volume":"76","author":"Latimer","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ana.22520","article-title":"Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study","volume":"70","author":"Launer","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(18)30461-7","article-title":"Association between circadian rhythms and neurodegenerative diseases","volume":"18","author":"Leng","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/WAD.0b013e318199fc7a","article-title":"Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases","volume":"23","author":"Longstreth","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1124\/pharmrev.120.000031_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-018-0275-4","article-title":"Exercise-linked FNDC5\/irisin rescues synaptic plasticity and memory defects in Alzheimer\u2019s models","volume":"25","author":"Lourenco","year":"2019","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000031_bib41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1096\/fj.05-5423fje","article-title":"Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK","volume":"20","author":"Maezawa","year":"2006","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000031_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-2094-3-21","article-title":"Apolipoprotein E isoform-dependent dendritic recovery of hippocampal neurons following activation of innate immunity","volume":"3","author":"Maezawa","year":"2006","journal-title":"J Neuroinflammation"},{"key":"10.1124\/pharmrev.120.000031_bib43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-016-1427-y","article-title":"Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders","volume":"94","author":"Mahley","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1124\/pharmrev.120.000031_bib44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.1928.02700150029009","article-title":"Punch drunk","volume":"91","author":"Martland","year":"1928","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000031_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneurol.2007.68","article-title":"Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders","volume":"65","author":"Mata","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-015-1515-z","article-title":"The first NINDS\/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy","volume":"131","author":"McKee","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000031_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000031_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1124\/pharmrev.120.000031_bib50","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer\u2019s fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000031_bib51","series-title":"Pathology of ischemic cerebrovascular disease. Neurosurgery. (Wilkins R and Rengachary S eds), vol 2","first-page":"2045","author":"Montine","year":"1996"},{"key":"10.1124\/pharmrev.120.000031_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000031_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.121","article-title":"Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease","volume":"47","author":"Musiek","year":"2015","journal-title":"Exp Mol Med"},{"key":"10.1124\/pharmrev.120.000031_bib54","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000031_bib55","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000031_bib56","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1128\/jvi.69.6.3584-3596.1995","article-title":"Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs","volume":"69","author":"Ou","year":"1995","journal-title":"J Virol"},{"key":"10.1124\/pharmrev.120.000031_bib57","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/NEN.0000000000000153","article-title":"Cerebral cortical A\u03b242 and PHF-\u03c4 in 325 consecutive brain autopsies stratified by diagnosis, location, and APOE","volume":"74","author":"Postupna","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","article-title":"Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study","volume":"11","author":"Reiman","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000031_bib59","first-page":"297","article-title":"Frontotemporal lobar degeneration: current perspectives","volume":"10","author":"Riedl","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1124\/pharmrev.120.000031_bib60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM198602203140806","article-title":"The pathogenesis of atherosclerosis--an update","volume":"314","author":"Ross","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000031_bib61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuroscience.2012.10.014","article-title":"Activity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespan","volume":"239","author":"Rothman","year":"2013","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.120.000031_bib62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-012-0996-2","article-title":"The genetics and neuropathology of Alzheimer\u2019s disease","volume":"124","author":"Schellenberg","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000031_bib63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00415-020-09705-7","article-title":"Precision medicine in Parkinson\u2019s disease: emerging treatments for genetic Parkinson\u2019s disease","volume":"267","author":"Schneider","year":"2020","journal-title":"J Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib64","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.111.178962","article-title":"Midlife blood pressure, plasma \u03b2-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study","volume":"59","author":"Shah","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pharmrev.120.000031_bib65","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000031_bib66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.24261","article-title":"Prioritized research recommendations from the national Institute of neurological disorders and stroke Parkinson\u2019s disease 2014 conference","volume":"76","author":"Sieber","year":"2014","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000031_bib67","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3233\/JPD-179009","article-title":"The birth of the modern era of Parkinson\u2019s disease genetics","volume":"7","author":"Singleton","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000031_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.freeradbiomed.2008.04.022","article-title":"Free radical-mediated damage to brain in Alzheimer\u2019s disease and its transgenic mouse models","volume":"45","author":"Sonnen","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/pharmrev.120.000031_bib69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archneurol.2008.579","article-title":"Different patterns of cerebral injury in dementia with or without diabetes","volume":"66","author":"Sonnen","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib70","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ana.21208","article-title":"Pathological correlates of dementia in a longitudinal, population-based sample of aging","volume":"62","author":"Sonnen","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib71","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1474-4422(19)30020-1","article-title":"Primum non nocere: a call for balance when reporting on CTE [published correction appears in Lancet Neurol (2019) 18:e3]","volume":"18","author":"Stewart","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0197-4580(00)00250-5","article-title":"Life span and synapses: will there be a primary senile dementia?","volume":"22","author":"Terry","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1124\/pharmrev.120.000031_bib74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1124\/pharmrev.120.000031_bib75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","article-title":"APOE \u03b54 increases risk for dementia in pure synucleinopathies","volume":"70","author":"Tsuang","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000031_bib76","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1124\/pharmrev.120.000031_bib77","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1532-5415.2009.02493.x","article-title":"Blood pressure and brain injury in older adults: findings from a community-based autopsy study","volume":"57","author":"Wang","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/pharmrev.120.000031_bib78","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/WNL.0000000000004608","article-title":"Traumatic brain injury may not increase the risk of Alzheimer disease","volume":"89","author":"Weiner","year":"2017","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000031_bib79","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.0000000000002480","article-title":"Neuropathologic comorbidity and cognitive impairment in the nun and Honolulu-Asia aging studies","volume":"86","author":"White","year":"2016","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000031_bib80","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000031_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2016.04.020","article-title":"Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer\u2019s disease mouse models","volume":"44","author":"Zhao","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1124\/pharmrev.120.000031_bib82","doi-asserted-by":"crossref","first-page":"eaay1809","DOI":"10.1126\/scitranslmed.aay1809","article-title":"APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid","volume":"12","author":"Zhao","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:16:17Z","timestamp":1739870177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724006495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0031699724006495"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000031","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive Impairment in Older Adults and Therapeutic Strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}